NCT02763969View on ClinicalTrials.gov

Safety Study of BMS-986202 in Healthy Subjects and to Treat Psoriasis

PHASE1CompletedINTERVENTIONAL
Enrollment

357

Participants

Timeline

Start Date

May 18, 2016

Primary Completion Date

December 15, 2016

Study Completion Date

December 15, 2016

Conditions
Psoriasis
Interventions
DRUG

BMS-986202

DRUG

Placebo

DRUG

Interferon alpha-2a recombinant

DRUG

Famotidine

DRUG

Ustekinumab

Trial Locations (2)

3004

Local Institution, Melbourne

Local Institution, Melbourne

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT02763969 - Safety Study of BMS-986202 in Healthy Subjects and to Treat Psoriasis | Biotech Hunter | Biotech Hunter